2,3-dinor, 6-keto-PGF1alpha

2,3-dinor, 6-keto-pgf1alpha is a lipid of Fatty Acyls (FA) class.

Cross Reference

There are no associated biomedical information in the current reference collection.

Current reference collection contains 782 references associated with 2,3-dinor, 6-keto-PGF1alpha in LipidPedia. Due to lack of full text of references or no associated biomedical terms are recognized in our current text-mining method, we cannot extract any biomedical terms related to diseases, pathways, locations, functions, genes, lipids, and animal models from the associated reference collection.

Users can download the reference list at the bottom of this page and read the reference manually to find out biomedical information.


Here are additional resources we collected from PubChem and MeSH for 2,3-dinor, 6-keto-PGF1alpha

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with 2,3-dinor, 6-keto-PGF1alpha

MeSH term MeSH ID Detail
Inflammation D007249 119 associated lipids
Diabetes Mellitus, Type 1 D003922 56 associated lipids
Diabetes Mellitus, Type 2 D003924 87 associated lipids
Body Weight D001835 333 associated lipids
Cardiovascular Diseases D002318 24 associated lipids
Tibial Fractures D013978 4 associated lipids
Thrombosis D013927 49 associated lipids
Endometriosis D004715 29 associated lipids
Liver Cirrhosis D008103 67 associated lipids
Cerebral Hemorrhage D002543 13 associated lipids
Per page 10 20 50 | Total 25

NCBI Entrez Crosslinks

All references with 2,3-dinor, 6-keto-PGF1alpha

Download all related citations
Per page 10 20 50 100 | Total 191
Authors Title Published Journal PubMed Link
Tanaka H et al. Can urinary eicosanoids be a potential predictive marker of clinical response to thromboxane A2 receptor antagonist in asthmatic patients? 1999 Respir Med pmid:10653051
Mizugaki M et al. Monitoring of the thromboxane A2/prostacyclin ratio in the urine of patients with retinal vascular occlusion through the low-dose-aspirin therapy using the gas chromatography/selected ion monitoring method. 1999 Prostaglandins Other Lipid Mediat. pmid:10593167
Hishinuma T et al. Urinary thromboxane A2/prostacyclin balance reflects the pathological state of a diabetic. 1999 Prostaglandins Other Lipid Mediat. pmid:10593168
Hoch B and Bernhard M Reduced prostacyclin to thromboxane A2 ratio is correlated with central apneas in preterm infants. 1999 Prostaglandins Other Lipid Mediat. pmid:10593170
Regan CL et al. Reduced fetal exposure to aspirin using a novel controlled-release preparation in normotensive and hypertensive pregnancies. 1998 Br J Obstet Gynaecol pmid:9692413
Lindström T et al. The effect of unreamed and reamed intramedullary nailing on the urinary excretion of prostacyclin and thromboxane A2 metabolites in patients with tibial shaft fractures. 1998 J Trauma pmid:9783614
Moutquin JM et al. Do prostacyclin and thromboxane contribute to the "protective effect" of pregnancies with chronic hypertension? A preliminary prospective longitudinal study. 1997 Am. J. Obstet. Gynecol. pmid:9423755
Rossi P et al. Percutaneous transluminal angioplasty increases thromboxane A2 production in claudicants. 1997 Prostaglandins Leukot. Essent. Fatty Acids pmid:9175173
Rautanen M et al. Experimental fat embolism induces urine 2,3-dinor-6-ketoprostaglandin F1alpha and 11-dehydrothromboxane B2 excretion in pigs. 1997 Crit. Care Med. pmid:9233750
Henrion D et al. Alteration of flow-induced dilatation in mesenteric resistance arteries of L-NAME treated rats and its partial association with induction of cyclo-oxygenase-2. 1997 Br. J. Pharmacol. pmid:9146891